A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma
| Autor: | Abdeljabar El Andaloussi, Marie-Denise Poirier, Houda Haban |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Article Subject
medicine.drug_class medicine.medical_treatment chemical and pharmacologic phenomena Monoclonal antibody lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Immune system Glioma Medicine IL-2 receptor 030304 developmental biology 0303 health sciences business.industry hemic and immune systems Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 3. Good health CTL medicine.anatomical_structure Oncology Immunology Systemic administration Bone marrow business Research Article 030215 immunology |
| Zdroj: | Journal of Oncology Journal of Oncology, Vol 2009 (2009) |
| ISSN: | 1687-8469 1687-8450 |
| DOI: | 10.1155/2009/963037 |
| Popis: | Abrogating the suppression of glioma-infiltrating Tregs in the periphery and the central nervous system is essential to successful glioma rejection. We sought to improve the immune response in glioma-bearing mice, by investigating new strategies using the anti-CD25 immunotherapy. We found a complete long-term survival of glioma-bearing mice treated with a combination of systemic and intracranial anti-CD25 mAb immunotherapy as compared to systemic administration of anti-CD25 mAb. In addition, the group of mice that had been cured by the combined anti-CD25 mAb showed long-term survival without late tumor relapse when challenged with the GL261 glioma. The antitumor immune response was investigated by analysis of antitumor immune response (CTL). Results showed that the use of the combined injections of anti-CD25 mAb induced efficient targeting of Tregs expansion inside and outside of the brain and altered Tregs trafficking in the bone marrow and brain areas where antitumor immunity was primed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text